TCGA-AO-A03P-01A-11R-A00Z-07
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
- overall_survival_months
- 97
- os_event
- true
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V1+0.550
- MYC_TARGETS_V2+0.470
- E2F_TARGETS+0.410
- G2M_CHECKPOINT+0.310
- DNA_REPAIR+0.270
- PANCREAS_BETA_CELLS+0.260
- UNFOLDED_PROTEIN_RESPONSE+0.260
- OXIDATIVE_PHOSPHORYLATION+0.250
- ESTROGEN_RESPONSE_EARLY+0.170
- ESTROGEN_RESPONSE_LATE+0.140
Top 10 suppressed
- NOTCH_SIGNALING-0.480
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.460
- ANGIOGENESIS-0.430
- INFLAMMATORY_RESPONSE-0.390
- TNFA_SIGNALING_VIA_NFKB-0.380
- APICAL_JUNCTION-0.370
- IL6_JAK_STAT3_SIGNALING-0.370
- IL2_STAT5_SIGNALING-0.360
- KRAS_SIGNALING_UP-0.350
- CHOLESTEROL_HOMEOSTASIS-0.340
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BSR_04_0040_A3_S71 | — | B | 0.897 |
| 2 | 20110028.LumB | — | B | 0.888 |
| 3 | TCGA-AO-A0J3-01A-11R-A034-07 | — | B | 0.884 |
| 4 | SRR4195684 | — | — | 0.869 |
| 5 | SRR25617899 | — | B | 0.862 |
| 6 | SRR8518412 | — | B | 0.859 |
| 7 | TCGA-66-2756-01A-01R-0851-07 | — | cohortA3 | 0.855 |
| 8 | BS_M84H3KXA | medulloblastoma | — | 0.852 |
| 9 | TCGA-B6-A0RL-01A-11R-A084-07 | — | B | 0.847 |
| 10 | TCGA-51-4080-01A-01R-1100-07 | — | cohortSQ2 | 0.847 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 16 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V1 | 0.550 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.470 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.410 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.310 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.270 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.260 | Cobimetinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.260 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.250 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.170 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.140 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.110 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.100 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.080 | Remibrutinib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.070 | Inavolisib | — uncovered |
| PEROXISOME | 0.060 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.060 | Inavolisib | — uncovered |